Patent application

European travel information and authorisation system (ETIAS): Council Presidency and European Parliament provisionally agree on rules for accessing relevant databases

Retrieved on: 
Friday, March 19, 2021
Patent application, Multi-speed Europe, Human migration, Chemical safety, Toxicology

The Council presidency and European Parliament representatives today reached a provisional agreement on the rules connecting the ETIAS central system to the relevant EU databases.

Key Points: 
  • The Council presidency and European Parliament representatives today reached a provisional agreement on the rules connecting the ETIAS central system to the relevant EU databases.
  • The agreed texts will next be submitted to the relevant bodies of the Council and the Parliament for political endorsement and, following this, for their formal adoption.
  • The information submitted in each application will be automatically processed against EU and relevant Interpol databases to determine whether there are grounds to refuse a travel authorisation.
  • For each application, the applicant will be required to pay a travel authorisation fee of 7 euros.

Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics

Retrieved on: 
Thursday, March 18, 2021
Hallucinations, Patent application, Provisional application, Psychedelic drug, Filing, Law, Government

The provisional patent describes novel methods for the formulation, delivery, and dosing of psychedelics resulting in a potential reduction in the time spent by patients in the dissociative state.

Key Points: 
  • The provisional patent describes novel methods for the formulation, delivery, and dosing of psychedelics resulting in a potential reduction in the time spent by patients in the dissociative state.
  • These proprietary methods represent the foundational elements of the comprehensive medical treatment program Tryp is developing for a wide variety of conditions.
  • This filing is expected to be the first of a series of patent filings to enhance the effectiveness of psychedelics and to further differentiate Tryp's intellectual property position.
  • The filing includes a method for measuring the response to psychedelic therapeutics, further supporting a more controlled psychedelic experience.

European Patent Office Report Shows U.S. Patent Applications Fell by 4% During Pandemic

Retrieved on: 
Tuesday, March 16, 2021
Countries, Intellectual property law, Law, European Patent Organisation, European Patent Office, European Patent Convention, Patent application

The overall number of European patent applications across all countries filed in 2020 remained stable, decreasing by 0.7% compared with the previous year.

Key Points: 
  • The overall number of European patent applications across all countries filed in 2020 remained stable, decreasing by 0.7% compared with the previous year.
  • The EPO received 180,250 patent applications in total, which was slightly below the record level attained in 2019 (181,532).
  • The U.S. nonetheless remained the largest country of origin for European patent applications in 2020, accounting for almost a quarter of the total.
  • Peter Gorman, Shepard Fox Communications (USA), +1 617-669-4329, [email protected]
    Luis Berenguer Gimnez / Rainer Osterwalder, European Patent Office (EPO), +49 89 2399 1820, [email protected]

IMMUTEP SECURES SECOND UNITED STATES PATENT GRANT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR

Retrieved on: 
Tuesday, March 9, 2021
Patent law, Immutep, Eftilagimod alpha, Patent application, Divisional patent application, Term of patent, United States patent law

This United States patent was filed as a divisional application and follows the grant of the United States parent patent announced on 30 December 2020.

Key Points: 
  • This United States patent was filed as a divisional application and follows the grant of the United States parent patent announced on 30 December 2020.
  • The claims of this new patent build on the protection provided by the parent patent, and are directed to methods of treating cancer by administering Immuteps lead active immunotherapy candidate eftilagimod alpha (efti or IMP321) and a PD-1 pathway inhibitor.
  • The expiry date of the patent is 20 January 2036 (including a patent term adjustment of 12 days).
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain

Retrieved on: 
Monday, March 8, 2021
Pharmaceutical, Health, Other Health, Intellectual property law, Intellectual property organizations, United States Patent and Trademark Office, United States trademark law, Patent application, Patent

The patent application was filed on October 1, 2018.

Key Points: 
  • The patent application was filed on October 1, 2018.
  • The latest patent approval adds to the Companys existing patent portfolio, which includes patent issuances by the USPTO for seizure disorders and eating disorders.
  • IGC operates two lines of business: (i) infrastructure and (ii) life sciences.
  • The Company is based in Potomac, Maryland, U.S.A. social media: www.igcinc.us , www.igcpharma.com , Twitter @IGCIR.

MySize Receives Notice of Allowance from the Japan Patent Office for MySizeID Smart Measurement Solution

Retrieved on: 
Thursday, March 4, 2021
Patent application, Bra size, Handheld game console, Patent, Software sizing, Sizing, Computing, Visual arts, Computer science

The patent application encompasses the methods and systems for measuring a body part of a user via a handheld electronic device.

Key Points: 
  • The patent application encompasses the methods and systems for measuring a body part of a user via a handheld electronic device.
  • The result is that customers enjoy highly accurate sizing information based on the users' exact measurements.With this latest patent, MySize has ten total issued patents and nine patent applications pending globally.
  • Please click here for a demonstration of how MySizeID provides a full sizing solution for the retail industry.
  • Forward-looking statements also are affected by the risk factors described in the Company's filings with the U.S. Securities and Exchange Commission.

Mitsubishi Electric 1st Among Japanese Firms and 3rd Globally in International Patent Applications Filed in 2020

Retrieved on: 
Wednesday, March 3, 2021
Consumer electronics, Technology, Manufacturing, Software, Other Manufacturing, Hardware, Countries, Government, Foreign relations, Intellectual property law, Patent Cooperation Treaty, Patent application, Intellectual property organization, Patent, World Intellectual Property Organization, Term of patent

Mitsubishi Electric Corporation (TOKYO:6503) announced today that it ranked first among Japanese firms and third globally in terms of international patent applications filed in 2020 according to an announcement by the Switzerland-based World Intellectual Property Organization (WIPO) on March 2.

Key Points: 
  • Mitsubishi Electric Corporation (TOKYO:6503) announced today that it ranked first among Japanese firms and third globally in terms of international patent applications filed in 2020 according to an announcement by the Switzerland-based World Intellectual Property Organization (WIPO) on March 2.
  • The high rankings reflect Mitsubishi Electrics strategic positioning of intellectual property (IP) as a crucial business resource, including for R&D to support the companys sustainable growth.
  • Mitsubishi Electric has been actively filing international patent applications in line with its globalizing business.
  • Mitsubishi Electric has been particularly active in filing patent applications related to IoT- and AI-supported solutions in recent years.

NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data

Retrieved on: 
Tuesday, March 2, 2021
Countries, Foreign relations, Government, Entheogens, Drug discovery, Patent application, Provisional application, Patent Cooperation Treaty, Preclinical development, Psilocybin, Patent

To view an enhanced version of this graphic, please visit:

Key Points: 
  • To view an enhanced version of this graphic, please visit:
    The provisional patent applications include data derived from NeonMind's initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss.
  • NeonMind's proprietary preclinical data shows promise that both low and high dose psilocybin may reduce weight gain and that the reduction in weight gain can occur in a short period of time.
  • "We are encouraged with the preliminary results obtained from our preclinical trial," says NeonMind President & CEO Robert Tessarolo.
  • It has filed 10 US provisional patent applications, of which 2 have been converted to PCT applications.

PowerBuy Awarded US Patent 10,929,873 for Their Group Buying and Social Ecommerce Gamification Concept, Acquires Two New Advisory Board Members

Retrieved on: 
Wednesday, February 24, 2021
Intellectual property law, Pinduoduo, Gamification, Intellectual property organizations, United States Patent and Trademark Office, Patent application, Patent

IRVINE, Calif., Feb. 24, 2021 /PRNewswire/ --On Feb. 23, 2021, the US Patent and Trademark Office issued US Patent 10,929,873 to PowerBuy for their group buying and socialeCommerce gamification concept.

Key Points: 
  • IRVINE, Calif., Feb. 24, 2021 /PRNewswire/ --On Feb. 23, 2021, the US Patent and Trademark Office issued US Patent 10,929,873 to PowerBuy for their group buying and socialeCommerce gamification concept.
  • The issued patent, based on the originalapplication filed in March 2016 will help protect and solidify the group buying and social eCommerce gamification concept in the US.
  • PowerBuy, aSCaaS (Social Commerce as a Service) venture is continuing to lead the charge in group buying and eCommercegamificationin the US, similar to Pinduoduo in China.
  • Additionally, PowerBuy has also brought on two new members to their advisory board joining David Mason, Seth Demsey and Jayme Hoffman.

Hapbee Announces Filing of Provisional Patent Application for Bed-Related Form Factor

Retrieved on: 
Friday, February 19, 2021
Intellectual property law, United States patent law, International Searching and Preliminary Examining Authorities, Patent offices, Provisional application, Patent application, Patent, United States Patent and Trademark Office, Wearable, Magnetic field

VANCOUVER, BC, Feb. 19, 2021 /PRNewswire/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee"or the "Company"), a wellness technology company utilizing groundbreaking magnetic field technology in its Hapbee wearable, is pleased to announce it has filed a provisional patent application for its bed-related form factor with the United States Patent and Trademark Office ("USPTO").

Key Points: 
  • VANCOUVER, BC, Feb. 19, 2021 /PRNewswire/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee"or the "Company"), a wellness technology company utilizing groundbreaking magnetic field technology in its Hapbee wearable, is pleased to announce it has filed a provisional patent application for its bed-related form factor with the United States Patent and Trademark Office ("USPTO").
  • The provisional patent application covers a body support system that emits ultra-low radio frequency energy (ulRFE) expected to produce predefined sensations (e.g., calm, sleepy, relax, alert, focus).
  • Hapbee has completed the Industrial Design phase of prototype development for the aforementioned bed-related form factor and has entered the Engineering Design phase of the project.
  • Hapbee is a wearable magnetic field technology company that aims to help people choose how they feel.